Format

Send to

Choose Destination
Am J Transl Res. 2018 Aug 15;10(8):2234-2245. eCollection 2018.

New advances in immunotherapy for non-small cell lung cancer.

Author information

1
Department of Lung Cancer, 307th Hospital of Chinese People's Liberation Army Beijing 100071, China.

Abstract

Immunotherapy is one of the methods that can change the survival rate of patients with malignant tumors, in addition to surgery therapy, radiotherapy, chemotherapy and targeted therapy. Among various immunotherapy methods, immunoprecipitation inhibitors have been the most effective medications developed in recent years. At present, more in-depth studies have been conducted for two immune checkpoint inhibitor pathways, programmed cell death protein 1 (PD-1)/Programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and a variety of medications for those above mentioned. The present study briefly reviews the results of clinical trials for relevant immune checkpoint inhibitors in lung cancer.

KEYWORDS:

CTLA-4; NSCLC; PD-1/PD-L1; biomarkers; immunotherapy

PMID:
30210667
PMCID:
PMC6129543

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center